<PAGE> 1
Filed by Molecular Devices Corporation
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 of the
Securities Exchange Act of 1934
Subject Company: Molecular Devices Corporation
Corporation Commission File No.: 0-27316
Subject Company: LJL BioSystems, Inc.
Corporation Commission File No.: 0-23647
PRESS RELEASE
<TABLE>
<S> <C>
Contact: Tim Harkness Contact: Larry Tannenbaum
CFO/Vice President Finance CFO/Senior Vice President
Molecular Devices Corporation LJL BioSystems, Inc.
(408) 747-3533 (408) 548-0542
</TABLE>
MOLECULAR DEVICES AND LJL BIOSYSTEMS ANNOUNCE
TERMINATION OF HSR ACT WAITING PERIOD
SUNNYVALE, CA - JULY 28, 2000 - Molecular Devices Corporation (Nasdaq: MDCC) and
LJL BioSystems, Inc. (Nasdaq: LJLB) today announced the termination of the
applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement Act
of 1976. The Hart-Scott-Rodino Antitrust Improvement Act of 1976 prohibits the
closing of certain mergers and acquisitions prior to the expiration or
termination of any applicable waiting periods. As previously announced, on
Wednesday, August 30, 2000, the two companies will be holding their special
stockholders' meetings to consider and vote upon matters related to the merger
agreement entered into between the companies on June 7, 2000. The special
meeting of stockholders of Molecular Devices Corporation will be held on
Wednesday, August 30, 2000 at 10:30 a.m. (Pacific Time) at the corporate
headquarters of Molecular Devices located at 1311 Orleans Drive, Sunnyvale,
California. The special meeting of stockholders of LJL BioSystems, Inc. will be
held on Wednesday, August 30, 2000 at 9:00 a.m. (Pacific Time) at the corporate
headquarters of LJL BioSystems located at 405 Tasman Drive, Sunnyvale,
California. The record date for stockholders entitled to notice of, and to vote
at, the special meetings was July 14, 2000.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
Investors and security holders of both Molecular Devices and LJL BioSystems are
advised to read the joint proxy statement/prospectus regarding the potential
business combination transaction referred to above because it contains important
information. Molecular Devices and LJL BioSystems have mailed a joint proxy
statement/prospectus about the transaction to their respective stockholders.
This joint proxy statement/prospectus has been filed with the Securities and
Exchange Commission by both companies. Investors and security holders may obtain
a free copy of the joint proxy statement/prospectus and other documents filed by
the companies at the Securities and Exchange Commission's web site at
http://www.sec.gov. The joint proxy statement/prospectus and such other
documents may also be obtained from Molecular Devices or LJL BioSystems by
directing such requests to the companies.
<PAGE> 2
Molecular Devices and its officers and directors may be deemed to be
participants in the solicitation of proxies from Molecular Devices' stockholders
with respect to the transactions contemplated by the merger agreement.
Information regarding such officers and directors is included in Molecular
Devices' proxy statement for its 2000 annual meeting, filed with the Securities
and Exchange Commission. This document is available free of charge at the
Securities and Exchange Commission's web site at http://www.sec.gov and from
Molecular Devices.
LJL BioSystems and its officers and directors may be deemed to be participants
in the solicitation of proxies from stockholders of LJL BioSystems with respect
to the transactions contemplated by the merger agreement. Information regarding
such officers and directors is included in LJL BioSystems' Annual Report on Form
10-K for the fiscal year ended December 31, 1999 and in its proxy statement for
its 2000 annual meeting, filed with the Securities and Exchange Commission.
These documents are available free of charge at the Securities and Exchange
Commission's web site at http://www.sec.gov and from LJL BioSystems.
# # #
